A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT).

•ODYSSEY KT enrolled patients from South Korea and Taiwan.•ODYSSEY KT studied the efficacy and safety of alirocumab 75 up to 150 mg at 2-week intervals.•A pooled safety analysis was included from a broader patient population from Asia.•Alirocumab 75 up to 150 mg at 2-week intervals significantly reduced low-density lipoprotein cholesterol levels and other lipids.•Safety data were similar in ODYSSEY KT and the pooled analysis.